Everpride Biopharmaceutical receives 16.78 times over subscription

Everpride Biopharmaceutical (8019) announced that its placed 150mln shares, which were for the rights issue, had received 16.78 times over subscription from the institutional investors. Among the total of 150mln shares, 140mln shares were new, which were expected to raise HK$69.3mln based on the placing price of HK$0.495 each. If the underwriter exercised the over-allotment option and issued extra 22.5mln shares, the raised capital of the company would be increased to HK$80.44mln.

Related stock : (8019)